Skip to main
INSP
INSP logo

INSP Stock Forecast & Price Target

INSP Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 38%
Buy 33%
Hold 25%
Sell 4%
Strong Sell 0%

Bulls say

Inspire Medical Systems Inc. has demonstrated strong financial performance, with Q4 revenue reaching $239.7 million, reflecting a year-over-year increase of 24.5%, alongside earnings per share (EPS) of $1.15, outperforming consensus estimates. The consistent growth in utilization of the Inspire therapy, rising from 1.1 procedures per month in 2021 to an expected 1.8 in 2024, indicates increasing acceptance and demand for its neurostimulation technology. Additionally, the anticipated expansion in therapy penetration driven by new implanting centers, improved diagnosis rates, and upcoming innovations suggests significant growth potential for the company in both the U.S. and international markets.

Bears say

Inspire Medical Systems Inc faces a negative outlook due to several entrenched challenges, including slower penetration of implant centers, reduced utilization rates, and a protracted path to profitability. The firm is experiencing stagnation in its volume growth, heightened competition from new market entrants, and concerns over decreased physician reimbursement undermining the adoption of its procedure by new ENT specialists. Additionally, Inspire Medical's reliance on its sales force to drive treatment adoption, along with potential supply chain risks, may further impede its business growth prospects.

INSP has been analyzed by 24 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 33% recommend Buy, 25% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inspire Medical Systems Inc (INSP) Forecast

Analysts have given INSP a Buy based on their latest research and market trends.

According to 24 analysts, INSP has a Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $184.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $184.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inspire Medical Systems Inc (INSP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.